End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
2017 | Neol Biosolutions Seeks Investors | CI |
Sales 2015 | 1.21M 1.3M 104M | Sales 2016 | 2.59M 2.77M 222M | Capitalization | 13.76M 14.73M 1.18B |
---|---|---|---|---|---|
Net income 2015 | - 0 0 | Net income 2016 | -2M -2.14M -171M | EV / Sales 2015 | 23.8 x |
Net Debt 2015 | 17.66M 18.91M 1.51B | Net Debt 2016 | 17.5M 18.74M 1.5B | EV / Sales 2016 | 12.1 x |
P/E ratio 2015 |
128
x | P/E ratio 2016 |
-5.92
x | Employees | - |
Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 86.92% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | - | - | |
Corporate Officer/Principal | 57 | - | |
Corporate Secretary | 67 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 79 | 18/12/05 | |
Director/Board Member | 67 | - | |
Director/Board Member | - | - |
1st Jan change | Capi. | |
---|---|---|
-.--% | 5.19M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.90% | 22.25B | |
-14.77% | 21.68B | |
-8.70% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- NEU Stock